Caroline Fairbank

Caroline joins Initiate from J.P. Morgan, where she was a member of the biotech equity research team. There, her coverage universe included 30 clinical to commercial-stage biotech companies ranging from $500 K - $40 B market cap.

Prior to J.P. Morgan, Caroline was a life sciences consultant at ClearView Healthcare Partners where she focused primarily on M&A due diligence, global pricing and market access, and strategic support projects for biotech and pharmaceutical companies.

Caroline earned her bachelor’s degree in economics from Dartmouth College.